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and immunohistochemical studies in the kidney revealed theVasopeptidase inhibition and Ang-(1-7) in the spontaneously
existence of an intrarenal source, which may account for thehypertensive rat.
pronounced increase in the excretion rate of the vasodilatorBackground. Omapatrilat, a new vasopeptidase inhibitor,
heptapeptide. These findings provide further evidence for ainhibits the activity of angiotensin-converting enzyme (ACE)
contribution of Ang-(1-7) to the regulation of renal functionand neutral endopeptidase 24.11 (NEP). Because these two
and blood pressure.enzymes participate in the degradation of the vasodilator and
natriuretic peptide, angiotensin-(1-7) [Ang-(1-7)], we assessed
whether omapatrilat treatment is associated with changes in
the plasma and urinary excretion rates of the angiotensins.
Combined inhibition of both angiotensin-convertingMethods. We investigated in spontaneously hypertensive rats
enzyme (ACE) and neutral endopeptidase 24.11 has been(SHR) (0.24 kg body weight) the effect of omapatrilat on plasma
and urinary concentrations of angiotensin (Ang) I, Ang II and explored as a strategy to achieve a greater antihyperten-
Ang-(1-7) during 17 days of administration of either the drug sive effect through inhibition of angiotensin II (Ang II)
(N  15, 100 mol/kg/day) or vehicle (N  14) in the drinking production and metabolism of atrial natriuretic peptidewater. Hemodynamic and renal excretory function studies were
(ANP) [1, 2]. Omapatrilat is a newly developed vasopep-associated with histological examination of the expression of
tidase inhibitor with a dual action on both ACE andAng-(1-7) in the kidneys of both vehicle and omapatrilat-
treated SHRs. neutral endopeptidase 24.11 [2]. The potent antihyper-
Results. Omapatrilat induced a sustained lowering of systolic tensive effects of omapatrilat appear to be greater than
blood pressure (68 mm Hg) without changes in cardiac rate. those associated with ACE therapy [3–5], a finding thatThe mild positive water balance produced by omapatrilat did
suggests that the mode of action of this drug resultsnot cause natriuresis or kaliuresis, although it was associated
from the additional potentiating effect of augmentingwith a significant decrease in urine osmolality. Blood pressure
normalization was accompanied by increases in plasma Ang I the counterbalancing role of the natriuretic peptide sys-
(2969%), Ang II (57%), and Ang-(1-7) (163%) levels, parallel- tem on blood pressure. To the extent that neutral endo-
ing pronounced increases in urinary excretion rates of Ang I peptidase inhibition may also affect the degradation ofand Ang-(1-7) but not Ang II. Detection of Ang-(1-7) immuno-
angiotensin-(1-7) [Ang-(1-7)] [6, 7], we investigated thestaining in the kidneys of five other SHR exposed either to
effects of omapatrilat on the fate of both the plasmavehicle (N  3) or omapatrilat (N  2) ascertained the source
of the Ang-(1-7) found in the urine. Intense Ang-(1-7) staining, and kidney renin-angiotensin systems. The study was
more pronounced in omapatrilat-treated SHR, was found in prompted by the demonstration that urinary excretion
renal proximal tubules throughout the outer and inner regions rates of Ang-(1-7) were markedly elevated in salt-sensi-of the renal cortex and the thick ascending loop of Henle,
tive hypertensive subjects in response to oral administra-whereas no Ang-(1-7)-positive immunostaining was found in
tion of omapatrilat [1].glomeruli and distal tubules.
Conclusions. Omapatrilat antihypertensive effects caused
significant activation of the renin-angiotensin system associ-
ated with increases in urinary excretion rates of Ang I and METHODS
Ang-(1-7). Combined studies of Ang-(1-7) metabolism in urine Experiments were done in 29 aged-matched (10-week-
old) male spontaneously hypertensive rats (SHR) (Charles
River, Wilmington, MA, USA) in accordance with theKey words: hypertension, omapatrilat, angiotensin peptides, angioten-
sin-(1-7). guidelines set forth by the Animal Care and Use Com-
mittee of the Wake Forest University School of Medi-Received for publication February 27, 2002
cine. At the initiation of the study the body weight ofand in revised form April 12, 2002
Accepted for publication May 8, 2002 SHR averaged 242 3 g. Rats were housed in metabolic
cages (Harvard Bioscience, South Natick, MA, USA) in 2002 by the International Society of Nephrology
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a room maintained at 25  2C on a 12-hour light/dark concentration of 100 mol/L) in the presence or absence
of 1 mol/L omapatrilat for up to 60 minutes at 37C.cycle and fed a powdered rat chow (Purina Mills, Inc.,
Richmond, IN, USA), providing a daily intake of 17 Aliquots were taken at various times into 0.2% phos-
phoric acid and the metabolism of Ang-(1-7) was deter-mEq sodium and 28 mEq potassium per 100 g of solid
weight. mined by high pressure liquid chromatography (HPLC)
analysis as described previously [6]. The data were ex-
Experimental protocol pressed as the percentage of Ang-(1-7) remaining at a
given time as compared to control [urine  0.2% phos-Rats were assigned randomly to drink either tap water
or water to which a solution of omapatrilat was added phoric acid  Ang-(1-7)]. The half-life (t1/2) of the pep-
tide was calculated from a nonlinear regression exponen-to provide a daily intake of 100mol/kg/day of omapatri-
lat for up to 17 days. tial decay curve using the Prism plotting and statistical
program (Graph Pad, San Diego, CA, USA).Twenty-four-hour water and food intake, urine vol-
ume, and urine sodium and potassium excretion were
Angiotensin-(1-7) immunocytochemistrymeasured for 3 days before and at regular intervals after
initiation of the drug treatment. Systolic blood pressure Kidneys from three vehicle-treated and two omapatri-
lat-dosed animals were placed immediately in a solutionwas measured before and throughout the treatment pe-
riod by the tail cuff method (Narco Bio-systems, Hous- of 4% formalin acetate. Tissue was left in 4% formalin
for 24 to 48 hours before being transferred to 70% ethanol.ton, TX, USA). Heart rate was derived from counting
of the pulse waves visualized in the oscilloscope’s screen. Kidney tissue was then imbedded in paraffin and five
m sections were transferred to subbed slides deparaf-At the completion of the treatment period, rats were
sacrificed by decapitation and the heart was removed, finized by sequential washes with xylene, 100% ethanol,
95% ethanol, 75% ethanol, and double distilled water.blotted dry and weighed.
Tissue sections were then incubated with 3% hydrogen
Laboratory procedures peroxide for 5 minutes, washed with phosphate-buffered
saline (PBS; pH 7.2), dried, and incubated with 5% nor-The concentrations of electrolytes in aliquots of urine
were determined using the Nova Biomedical Electrolyte mal goat serum for 1 hour at room temperature. Sections
were then washed with PBS and incubated overnight atAnalyzer (Waltham, MA, USA), whereas the concentra-
tion of creatinine was measured photometrically (Sigma 4C with an affinity-purified rabbit polyclonal antibody
to Ang-(1-7) at 1:25 dilution of the antibody in 1% BSA.Chemical Co., St Louis, MO, USA).
Urinary concentrations of Ang I, Ang II and Ang-(1-7) The Ang-(1-7) antibody was purified and characterized,
as described elsewhere [10]. The next day, tissues werewere determined by radioimmunoassay, as described in
detail elsewhere [8]. Urine was extracted using Sep-Pak washed with PBS and incubated for 3 hours at 4C with
a biotinylated anti-rabbit antibody at a dilution of 1:400columns activated with 5 mL sequential washes of a mix-
ture of ethanol:water:4% acetic acid (83:13:4), methanol, in 1% BSA. Slides were rinsed with PBS, blotted dry, and
reacted immunocytochemically using the avidin-biotinultra-pure water, and 4% acetic acid. The sample was ap-
plied to the column, washed with ultra-pure water and method (Vector Laboratories, Burlingame, CA, USA)
[11] and stained brown with 33’-diaminobenzidine (Sigmaacetone and eluted with two 1 mL and one 1.5 mL washes
of a mixture of ethanol:water:4% acetic acid. The weight Chemical Co.) in Tris-buffered saline (0.05 mol/L, pH
7.6-7.7). The reaction was stopped in PBS and sectionsof the eluate was recorded and, from the total eluate,
aliquots were transferred into conical bottom polystirene rinsed in double distilled water before being counter-
stained with Harris hematoxylin (Sigma Chemical Co.).tubes and dried. The eluted sample was reconstituted
into a Tris buffer with 0.1% bovine serum albumin (BSA). Tissue sections were dehydrated in ethanol (70% to
100%) and then rinsed in Histoclear (National Diagnos-The concentrations of angiotensin peptides were mea-
sured by radioimmunoassay, using antibodies described tics, Atlanta, GA, USA). Finally, they were cover-slipped
using Histomount (National Diagnostics). The specificitypreviously [9]. Recoveries of radiolabeled angiotensin
added to the sample and followed through the extraction of the staining using the Ang-(1-7) antibody was deter-
mined by pre absorption of the Ang-(1-7) antibody withaveraged 88%. Samples were corrected for recoveries,
as described elsewhere [8]. 10 mol/L Ang-(1-7). Nonimmune rabbit serum was fur-
ther used as a control for the validity of the stainingUrine samples collected overnight from untreated
SHR rats (10 weeks of age) were pooled and dialyzed procedure.
against 10 mmol/L N-2 hydroxyethylpiperazine-N’-2-
Statistical analysisethanesulfonic acid (HEPES), 125 mmol/L sodium chlo-
ride (NaCl) pH 7.4 and concentrated on a 30,000 D filter All data are expressed as mean  SE. Differences
across time for both the treatment and control groups(Millipore, Bedford, MA, USA). Ang-(1-7) (Bachem,
Torrance, CA, USA) was added to 0.5 mL urine (final analyzed by repeated measures ANOVA followed by
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Table 1. Baseline values in spontaneously hypertensive rats
given vehicle or omapatrilat
Vehicle Omapatrilat
Variable (N  14) (N  15)
Systolic blood pressure mm Hg 1842 1923
Heart rate beats/min 2646 2697
Water intake mL 26.301.58 27.451.42
Urinary output mL 9.911.06 10.301.06
Creatinine excretion mg/dL 11532 12015
Urinary Ang I excretion fmol/24 hours 3932359 4509635
Urinary Ang II excretion fmol/24 hours 840140 1043130
Urinary Ang-(1-7) excretion fmol/24 hours 3755471 4260422
Urinary sodium excretion mEq/24 hours 1.690.09 1.770.08
Urinary potassium excretion mEq/24 hours 2.440.30 2.900.16
Urinary osmolality mOsm/L 184180 1811104
Body weight g 2424 2424
Values are means  SEM.
Scheffes post hoc test. Differences between groups were
analyzed by the Student t test and P values less than or
equal to 0.05 were considered statistically significant.
RESULTS
Hemodynamic and renal excretory effects
of omapatrilat
Baseline hemodynamic, water intake, and urinary
electrolytes and excretion variables did not differ be-
tween SHR randomized to receive either tap water or
omapatrilat (Table 1). As illustrated in Figure 1, SHR
medicated with omapatrilat showed a progressive and
significant decrease in systolic blood pressure that
Fig. 1. Average changes in tail-cuff systolic blood pressure. (A) Vehiclereached a plateau within 10 days after commencement
() and (B) omapatrilat-treated SHR () during a 17-day dosing pe-of the treatment period. On day 16, average systolic riod. Values are means  SE. *P  0.01 compared to vehicle.
blood pressure in omapatrilat-treated rats was 122 
5 mm Hg compared to 190 3 mm Hg in vehicle-treated
rats (P  0.001). The antihypertensive response was as-
sociated with no changes in heart rate (Fig. 1), but a
significant decrease in heart weight (812  27 mg com-
pared to 977  31 mg in vehicle-treated controls, P 
0.02). There were no differences in body weights of rats
randomized to either vehicle (273  5 g) or omapatrilat
(265 5 g, P	 0.05) at the end of the treatment regimen
and the medication had no significant effect on food
intake when compared to vehicle-treated rats.
Plasma levels of angiotensin peptides in vehicle- and
omapatrilat-treated rats at the completion of the treat-
ment period are illustrated in Figure 2. Omapatrilat
caused large elevations in plasma concentrations of
Ang I, Ang II, and Ang-(1-7), amounting to 2969%,
57%, and 163% of values found in vehicle-treated SHR,
respectively. The rise in Ang I concentrations resulted
in a significant decrease in the Ang II/Ang I ratio to
Fig. 2. Omapatrilat causes a significant increase in plasma concentra-values averaging 0.15  0.04 in omapatrilat-treated rats
tions of angiotensins [Ang I, Ang II, and Ang-(1-7)] at day 17 of treatment
compared to an Ang II/Ang I ratio of 1.73  0.39 in period. Values are means  SE of SHR given either vehicle () or
omapatrilat (). *P  0.02; ** P  0.001.vehicle-treated controls (P 0.001). In addition, omapa-
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Fig. 3. Effect of chronic exposure to omapatrilat () compared to vehicle-treated controls (). (A) cumulative water intake. (B) Urine volume.
(C ) urine osmolality. (D) urinary sodium excretion. (E) Urinary potassium excretion. (F ) Food consumption. Values are means  SE; *P  0.05
compared to vehicle.
trilat reduced the Ang-(1-7)/Ang I in omapatrilat-treated mL/24 hours (P  0.002), whereas it did not change
in SHR given the vehicle (26.30  1.58 mL/24 hoursrats averaged 0.11  0.02 compared to 1.09  0.17 in
vehicle-treated controls (P  0.001). compared to 25.95  0.98 mL/24 hours, P 	 0.05) at the
end of the study period). Figure 3 also shows that theOmapatrilat treatment resulted in a progressive rise in
cumulative fluid balance as water intake was significantly polyuria in omapatrilat-treated SHR was associated with
a significant and sustained fall in urinary osmolality,augmented over the accompanying increases in urinary
volume (Fig. 3). In omapatrilat-treated rats, water intake whereas urinary excretion rates of either sodium or po-
tassium did not change.increased from 27.45 1.42 mL/24 hours to 49.87 2.19
Ferrario et al: Omapatrilat and Ang-(1-7) 1353
At baseline, angiotensin peptides were detected in the
urine of both vehicle and omapatrilat-treated SHR at
concentrations not different from those previously re-
ported elsewhere [12]. Initiation of omapatrilat treat-
ment was associated with significant increases in the ex-
cretion rates of Ang I and Ang-(1-7), whether the data
were expressed either in terms of concentrations or in
terms of 24-hour excretion rates (Fig. 4). Changes in the
excretion rate of urinary Ang II were not statistically
significant (P 	 0.05).
Multiple regression analysis of the combined data
from vehicle- and omapatrilat-treated SHR (Table 2)
showed that systolic blood pressure was negatively corre-
lated with heart rate, urinary volume, urine osmolality,
water intake, and urinary excretion rates of Ang I and
Ang-(1-7). Systolic blood pressure showed a direct corre-
lation with urinary osmolality, an inverse correlation
with both urine volume and Ang-(1-7), and no significant
correlation with Ang II.
Evaluation of the source of Ang-(1-7) in urine
The rate of Ang-(1-7) hydrolysis in the urine of un-
treated SHR in the absence and presence of 1 mol/L
omapatrilat was evaluated in dialyzed urine collected
from untreated SHR. As shown in the chromatograph
(Fig. 5A), Ang-(1-7) added to urine was hydrolyzed pri-
marily to Ang-(1-4) and Ang-(1-5). Addition of omapa-
trilat essentially abolished production of both metabo-
lites, while substantially increasing the peak of Ang-(1-7)
in the chromatogram. The time course for the metabo-
lism of Ang-(1-7) in urine before (control) or after addi-
tion of omapatrilat is documented (Fig. 5B). Incubation
of urine with omapatrilat caused a six-fold increase (5.2
minutes vs. 33 minutes) in the Ang-(1-7) half-life.
A composite of sections of kidneys obtained from
SHR is shown given either vehicle (Fig. 6 A and C) or
omapatrilat (Fig. 6 B and D) in their drinking water for
17 days. Ang-(1-7) immunostaining was found through-
out the renal cortex but absent in renal glomeruli. At
higher magnification, Ang-(1-7) immunostaining was vis-
ualized in the cytoplasm of renal proximal convoluted
tubules with a tendency for increased positive staining
around the basolateral and brush border of the proximal
tubules (Fig. 6C). No positive immunostaining is found Fig. 4. Excretion of angiotensins [Ang I (A), Ang II (B), and Ang-(1-7)
(C)] is markedly augmented throughout the 17-day duration of expo-in distal tubules. Figure 6D shows Ang-(1-7) labeling of
sure. Symbols are: omapatrilat (); SHR given vehicle (). Values arethick ascending limbs of loops of Henle in omapatrilat-
means  SE; *P  0.01 compared to vehicle.
treated SHR. Pre-absorption of the Ang-(1-7) antibody
with synthetic Ang-(1-7) and nonimmune rabbit serum
yielded no staining in all sections examined (Fig. 7).
association of the antihypertensive effect of the drug
with increases in the plasma concentrations of the angio-
DISCUSSION tensins and increases in urinary excretion rates of Ang I
These studies both confirm [4] and extend knowledge and Ang-(1-7); and (2) evidence that the changes in
of the effects of vasopeptidase inhibition in rats with urinary Ang-(1-7) reflect an intrarenal mechanism of
Ang-(1-7) secretion by renal tubules. Hemodynamically,spontaneous hypertension by demonstrating (1) a strong
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Table 2. Multiple regression analysis
Urinary
Heart Urine Urine Water Systolic
Variables rate volume osmolality intake Ang I Ang II Ang-(1-7) pressure
Heart rate beats/min 1.00
Urine volume mL 0.51 1.00
Urine osmolality mOsm/L 0.65 0.94 1.00
Water intake mL 0.55 0.99 0.93 1.00
Urinary Ang I fmol/mg 0.35 0.76 0.77 0.77 1.00
Urinary Ang II fmol/mg 0.18 0.55 0.49 0.54 0.71 1.00
Urinary Ang-(1-7) fmol/mg 0.49 0.98 0.93 0.96 0.81 0.63 1.00
Systolic pressure mm Hg 0.51 0.97 0.93 0.98 0.80 0.48 0.94 1.00
Multiple regression of analysis of combined date from vehicle- and omapatrilat-treated rats. Numbers in bold are statistically significant at a P value of at least 0.05.
diuresis and positive fluid balance, both urinary sodium
and potassium excretions were not different in rats given
vehicle or omapatrilat. In contrast, the normalization of
blood pressure induced by the vasopeptidase inhibitor
was associated with elevations in the plasma concentra-
tions of Ang I, Ang II, and Ang-(1-7), whereas only the
excretion rates of Ang I and Ang-(1-7) were markedly
elevated in omapatrilat-treated SHR. Assessment of
Ang-(1-7) metabolism in urine and detection of Ang-(1-7)
immunostaining in proximal renal tubules and the thick
ascending limb of the loop of Henle suggest an intrarenal
source for the presence of Ang-(1-7) in the tubular fluid.
These data suggest that the previously demonstrated ac-
tions of Ang-(1-7) in the regulation of renal function
[7, 13–18] may contribute to explain the mechanisms by
which omapatrilat manifests its potent antihypertensive
actions [1, 2, 19].
The sustained antihypertensive effect of omapatrilat
in SHR was associated with increases in plasma Ang I,
Ang II, and Ang-(1-7) levels, a finding that may reflect
a combination of enhanced renin release and activation
of a non-ACE-dependent pathway for Ang II formation
following inhibition of ACE [20, 21]. The increase in
plasma Ang-(1-7) levels is in keeping with the finding
that ACE is the enzyme responsible for the degradation
of the peptide into Ang-(1-5) [22], and that both vascular
endothelium prolyl endopeptidase (E.C. 3.4.24.26) and
smooth muscle thimet oligo peptidase (E.C. 3.4.24.15)
are capable of forming Ang-(1-7) [23, 24]. Therefore,
the effect of omapatrilat on inhibiting both ACE and
Fig. 5. Comparison of absorbance using high pressure liquid chroma- neutral endopeptidase 24.11 blocks the primary pathway
tography. (A) High pressure liquid chromatography (HPLC) of angio- for the degradation of Ang-(1-7), while allowing alterna-
tensin-(1-7) [Ang-(1-7)] metabolism in dialyzed rat urine for 15 minutes
tive Ang-(1-7)-forming enzymes to act on the increasedat 37C reveals conversion to Ang-(1-4) and Ang-(1-5) [control, solid
lines]. Addition of onemol/L omapatrilat [OMAP, dashed lines] atten- levels of Ang I substrate. This interpretation agrees also
uated generation of these angiotensin metabolites and increased the with the finding that inhibition of ACE is associated withrecovery of Ang-(1-7). (B) Time course for the hydrolysis of Ang-(1-7)
increased prolyl endopeptidase-like activity in plasmaat 37C in rat urine alone () or in the presence of omapatrilat ().
and lung [25].
We have previously documented that endothelial-
the sustained antihypertensive action of the vasopepti- derived ACE cleaves the Ile5 - His6 bond of Ang-(1-7)
dase inhibitor had no effect on cardiac rate but reversal to render Ang-(1-5), whereas in the kidney, neutral en-
of cardiac hypertrophy is inferred from a statistically dopeptidase 24.11 generates Ang-(1-4) through cleavage
of the Tyr4 – Ile5 bond of Ang-(1-7) [6, 7, 22]. The metabo-significant reduction in cardiac weight. Despite profuse
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Fig. 6. Photomicrographs of sections of kid-
neys. SHR given either vehicle (A) and (C )
or omapatrilat (B) and (D) for 17 days. (A)
and (C) from a vehicle-treated SHR shows
that Ang-(1-7) immunostaining is present in
renal proximal convoluted tubules throughout
the cortex while the medulla showed scant
Ang-(1-7)-positive staining cells. No immuno-
positive Ang-(1-7) staining is found in glomer-
uli. (B) shows an apparent increase in the den-
sity of Ang-(1-7) immunostaining in renal
proximal tubules, including increased immu-
nostaining now also found in the thick portion
of the ascending limb of Henle’s loops (D).
Magnification for (A) and (B) 
2; magnifica-
tion for (C) and (D) 
100.
lism studies in urine confirmed previous observations
that both tubular fluid and urine contain soluble forms
of these enzymes [26–29]. The time course of the changes
in the urinary concentrations of angiotensin peptides in
omapatrilat-treated SHR reinforces the view that their
presence in the urine reflects a renal source, a finding
that is in keeping with the detection of immunoreactive
Ang-(1-7) staining in tubular structures of the kidneys
of SHR. To our knowledge, our studies provide the first
direct evidence for the presence of Ang-(1-7) in the renal
tubular system, a finding that provides an underpinning to
several studies that showed important effects of Ang-(1-7)
in the regulation of renal function [7, 13–18]. The de-
tection of intense Ang-(1-7) immunoreactive staining in
renal tubules of both vehicle- and omapatrilat-treated
SHR suggests a potential mechanism for Ang-(1-7) se-
cretion into the lumen of renal tubules, as evidenced by
the finding that Ang-(1-7) is the major product of Ang
I metabolism in isolated proximal tubules [6]. Because
Ang I and Ang-(1-7) exist in urine at concentrations
much higher than Ang II [4, 12, 30], these data suggest
that tubular Ang II may be either destroyed locally or
taken up into the renal interstitium at rates much higher
than those of Ang I and Ang-(1-7).
The observation that the profuse diuresis produced by
Fig. 7. Preabsorption of the antibody with 10mol/L Ang-(1-7). Com-
plete elimination of staining is shown in an adjacent section from a
vehicle treated SHR. (A) Magnification 
25; (B) Magnifcation 
20.
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omapatrilat was accompanied by a significant decrease in patrilat on the metabolism of the atrial natriuretic pep-
urine osmolality, but maintenance of water and electro- tide is not a mechanism contributing to the antihyperten-
lyte balance is a new observation that implicates suppres- sive effect of the agent, our data now implicate Ang-(1-7)
sion of vasopressin as a component of the endocrine re- as an additional factor contributing to the potent anti-
sponse resulting from blockade of neutral endopeptidase hypertensive effects of omapatrilat. The detection of
24.11. In previous studies, we showed that the transient Ang-(1-7) in renal tubules and collecting ducts of SHR
diuresis and natriuresis produced for the first 3 days of a is a new and important finding providing an underlying
14-day continuous intravenous infusion of Ang-(1-7) in clue for the further and more precise investigation of
SHR was accompanied by suppression of plasma vaso- the effects of Ang-(1-7) in the regulation of renal func-
pressin concentrations and higher urinary excretion rates tion and tubular mechanisms controlling the excretion
of 6-keto prostaglandin F1 (6-keto-PGF1) [31]. These data of solutes and electrolytes.
suggest that local production of prostaglandins may also
contribute to inhibition of vasopressin action on renal ACKNOWLEDGMENTS
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